Mendelspod Podcast
The 21st is the Century of Biology. A radical advancement in the knowledge of basic biology and human disease is transforming our world. We interview the heroes beneath the headlines.
- Update frequency
- every 5 days
- Average duration
- 27 minutes
- Episodes
- 503
- Years Active
- 2014 - 2025
Preprints and the Future of Science Publishing with Jason Hoyt, PeerJ
A renewed effort has been underway by leading biologists this year to persuade their colleagues to preprint. This is the posting of a paper to an open access server before peer review and publicatio…
00:25:52 |
Mon 11 Apr 2016
Flipping Drug Development Upside Down: Niven Narain, BERG Health
The promise of rational drug design has driven pharma companies for years. The history of the industry has been one of trial and error, or “guess and check”, as scientists often say. Companies have…
00:27:21 |
Wed 06 Apr 2016
March 2016 with Nathan and Laura: Genomic Jenga and the Creator, the Anti-Abortion Lobby and Genetic Testing, and Theranos, Again
Which company offers the gold standard of sequencing? Nathan starts us out with a metaphor to compare linked reads with real long reads. Then it’s on to this month’s “knockout paper” that moves us …
00:21:31 |
Fri 01 Apr 2016
Medicine and the Limits of Science with Michel Accad, MD
Are drug prices really too high? If so, how do we bring them down? Is precision medicine and the use of molecular profiles really making a difference in healthcare today?
These are questions that re…
These are questions that re…
00:30:00 |
Wed 30 Mar 2016
How Good are Linked Reads? Serge Saxonov, 10X Genomics
When 10X Genomics launched their GemCode sequencing instrument at last year’s AGBT conference, what they offered seemed too good to be true. 10X was promising researchers a machine that could genera…
00:36:11 |
Tue 15 Mar 2016
A Home Run on the First Hit: PacBio’s Jonas Korlach
Jonas Korlach is a natural storyteller—a rare trait in a scientist who is more comfortable presenting data than talking of himself. Jonas is the co-inventor of PacBio’s SMRT (single molecule, real …
00:26:44 |
Tue 08 Mar 2016
Digital Pathology at Scale: Epic Sciences Takes CTC Technology to the Next Level
It’s the beginning of the age of liquid biopsies, when less invasive, regular blood draws will provide more information than the occasional solid tissue biopsy. Companies that offer tests based on c…
00:30:43 |
Thu 03 Mar 2016
February 2016: Mosquitos, Preprints, and that Rocking White House Summit
It’s time again to look back on another month with Nathan and Laura.
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelsp…
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelsp…
00:26:22 |
Tue 01 Mar 2016
BioNano Genomics Stakes Out Sequencing Territory as They Discover Lots of De Novo Variants in Reference Genome Projects
If you attended or followed the recent AGBT conference about all things sequencing, you probably saw a few BioNano Genomics t-shirts with the slogan, “Back to the Map.” They’re referring of course, …
00:32:25 |
Thu 25 Feb 2016
Is Oxitec Ready to Scale as Governments Seek Options to Control the Zika Virus?
With constant news topping the headlines about the Zika virus, a synthetic biology company out of Oxford England, Oxitec, has been getting some good press. For over ten years now, Oxitec has been dev…
00:25:42 |
Tue 23 Feb 2016
Human Genome Turns 15: Mike Hunkapiller
We’re all familiar with the announcement in the year 2000 by US President, Bill Clinton, and the UK’s Prime Minister, Tony Blair, that scientists had completed the first draft of the human genome. I…
00:27:10 |
Thu 04 Feb 2016
January 2016: Landergate, Grail, and Cancer Moonshot
“It being the month of Hypeuary, go hither through break in yonder wall called LanderGate, and thou wilt be on route to reach the Grail. Drink from this to find your Cure, and Death shall haunt you …
00:20:14 |
Mon 01 Feb 2016
Frontiers of Sequencing: Putting Long Reads and Graph Assemblies to Work
OK, so we get it. Long read sequencing technology is cool. But how cool? Is it another great player on the field, or does it change the game altogether?
This is a public episode. If you'd like to dis…
This is a public episode. If you'd like to dis…
00:32:01 |
Thu 28 Jan 2016
Why Drugs Are Priced So High and Diagnostics So Low
Pharma companies face escalated flack over high drug prices. Meanwhile the diagnostics industry toils away at comparative pennies to the dollar.
This is a public episode. If you'd like to discuss th…
This is a public episode. If you'd like to discuss th…
00:26:55 |
Thu 21 Jan 2016
Who Is John Ioannidis?
It’s now been over ten years since John Ioannidis published his now famous paper, Why Most Published Research Findings Are False. What response has John seen from the scientific community? How has …
00:31:19 |
Thu 14 Jan 2016
Cancer: Year in Review 2015 with Anna Barker
As we begin the countdown to the new year, we take a look back at 2015 in cancer research, treatment and prevention. Mendelspod is increasingly becoming known for the coverage of genomics and precis…
00:35:27 |
Wed 30 Dec 2015
Sci-Fi Author Kim Stanley Robinson Talks Life Science 2015
At the end of the year our goal is to bring the audience some unusual programming, some new outside perspectives on the topics we cover. As with last year, we talk today with science fiction writer, …
00:36:43 |
Tue 22 Dec 2015
Yes to FDA Regulation of LDTs, But We Need a New Framework, Says David Spetzler
We set up an interview with David Spetzler, the CSO of Caris Life Sciences, to hear about some promising new liquid biopsy tests they are developing. And we do that in today’s show. But first, the …
00:28:48 |
Thu 03 Dec 2015
Genomics and the Cloud Going Through “a Second Puberty,” says AWS’ Angel Pizarro
Angel Pizarro has watched as genomics and cloud computing have grown up together. Formerly a bioinformatics director at University of Pennsylvania, Angel is now the Technical Business Development M…
00:28:13 |
Tue 24 Nov 2015
Hot Biotech Market Neglects Stem Cell Therapies, Says CIRM's Neil Littman
In 2004, California voters approved Prop 71 to fund the field of stem cell research by setting up the California Institute of Regenerative Medicine, or CIRM, with $3 billion. George W. Bush was in t…
00:23:16 |
Wed 18 Nov 2015
Disclaimer: The podcast and artwork embedded on this page are the property of Theral Timpson. This content is not affiliated with or endorsed by eachpod.com.